Case Based Panel Discussion - Advanced Non Squamous NSCLC, High PD-L1, No Driver Mutation - What is the Optimal 1st Line?

H. Jack West, MD, Founder, President and CEO

Dr. Jack West recently had the privilege to spend time with Drs Zofia Piotrowska, and Taofeek Owonikoko for a series of case-based discussions.   

Dr. Zofia Priotrowska is with the Thoracic Oncology Program at Massachusetts General Hospital Cancer Center in Boston, Massachusetts.  

Dr. Taofeek Owonikoko is a Professor with the Department of Hematology and Medical Oncology at Emory University School of Medicine, and Co-Chair of the Clinical and Translational Review Committee at Winship Cancer Institute.  

In this series of videos, the doctors sat down to discuss a series of case-based scenarios.   In this video, the doctors discuss the optimal 1st line for a patient with advanced non-squamous non-small cell lung cancer, high PD-L1, and no driver mutation.

Video Language: 


Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation